For instance, if one of the previously identified NSCLC-associated genes, such as EGFR, ALK, ROS1, BRAF, RET, MET, or NTRK, is mutated in the patient’s cancer cells, targeted therapies has to be considered [1]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.